Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

心房細動のカルディオバージョン後の洞調律維持を目的とした抗不整脈薬

Esta versión no es la más reciente

Información

DOI:
https://doi.org/10.1002/14651858.CD005049.pub3Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 16 mayo 2012see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Corazón

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Carmelo Lafuente‐Lafuente

    Correspondencia a: Service de Gériatrie à orientation Cardiologique et Neurologique, Groupe hospitalier Pitié‐Salpêtrière‐Charles Foix, AP‐HP, Université Pierre et Marie Curie (Paris 6), Ivry‐sur‐Seine, France

    [email protected]

    [email protected]

  • Miguel Angel Longas‐Tejero

    Servicio de Cardiología, Hospital universitario Príncipe de Asturias, Madrid, Spain

  • Jean‐François Bergmann

    Service de Médecine Interne A, Hôpital Lariboisière, AP‐HP, Université Paris 7 Diderot, Paris, France

  • Joël Belmin

    La Triade ‐ Service hospitalo‐universitaire de Gérontologie, Université Pierre et Marie Curie (Paris 6), Paris, France

Contributions of authors

Carmelo Lafuente‐Lafuente: prepared and designed the protocol, searched for primary studies, assessed papers for inclusion and quality, extracted data, performed analysis and interpreted data, contacted authors of primary studies when needed and wrote the review.

Miguel Angel Longás‐Tejero: screened search results, retrieved papers, assessed papers for inclusion and quality, extracted data from papers and wrote the review.

Joël Belmin: assessed papers for inclusion and quality, extracted data from papers, interpreted data and reviewed the manuscript.

Jean François Bergmann: designed the review, assessed papers for inclusion and quality, interpreted data and reviewed the manuscript.

Sources of support

Internal sources

  • Unité de Recherches Thérapeutiques, Hôpital Lariboisière, Paris, France.

  • Assistance Publique ‐ Hôpitaux de Paris, France.

External sources

  • No sources of support supplied

Declarations of interest

Carmelo Lafuente‐Lafuente has received consultant fees (less than 5 000 € total) from Sanofi‐Aventis, in 2009 and 2010, for helping to conduct a study (a mixed treatment comparison meta‐analysis) on several antiarrhythmic drugs for the management of atrial fibrillation. Sanofi‐Aventis is the manufacturer of amiodarone and dronedarone, two of the antiarrhythmics studied in this review.

Acknowledgements

We thank all the authors who answered our request for additional data; Pr. Charles Caulin for his most valuable suggestions; Dr. Barbara Stadler for translating articles from German; Lone Gale for helping with articles in Sweden, Dr. Qian Zhang for translating from Chinese, and all the staff of Cochrane Heart Group for their most important help and support.

Version history

Published

Title

Stage

Authors

Version

2019 Sep 04

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

Review

Lucie Valembois, Etienne Audureau, Andrea Takeda, Witold Jarzebowski, Joël Belmin, Carmelo Lafuente‐Lafuente

https://doi.org/10.1002/14651858.CD005049.pub5

2015 Mar 28

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

Review

Carmelo Lafuente‐Lafuente, Lucie Valembois, Jean‐François Bergmann, Joël Belmin

https://doi.org/10.1002/14651858.CD005049.pub4

2012 May 16

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

Review

Carmelo Lafuente‐Lafuente, Miguel Angel Longas‐Tejero, Jean‐François Bergmann, Joël Belmin

https://doi.org/10.1002/14651858.CD005049.pub3

2007 Oct 17

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

Review

Carmelo Lafuente‐Lafuente, Stephane Mouly, Miguel Angel Longas‐Tejero, Jean‐François Bergmann

https://doi.org/10.1002/14651858.CD005049.pub2

2004 Oct 18

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation

Protocol

Carmelo Lafuente‐Lafuente, Stephane Mouly, Miguel Angel Longas‐Tejero, Jean François Bergmann

https://doi.org/10.1002/14651858.CD005049

Differences between protocol and review

None of the methods or the outcomes stated in the original protocol were modified. Some of the outcomes and planned subgroup analysis could not be performed because the data needed were not recorded or not reported in the original studies.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.